Antibiotic versus cranberry in the treatment of uncomplicated urinary infection: a randomized controlled trial

Güven, Oya; Sayılan, Samet; Tataroğlu, Özlem; Hökenek, Nihat Müjdat; Keleş, Dilek Vural

doi:10.1590/1806-9282.20230799

Acessibilidade / Reportar erro

Brasil

Revista da Associação Médica Brasileira

Español English

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

Original Article • Rev. Assoc. Med. Bras. 70 (1) • 2024 • https://doi.org/10.1590/1806-9282.20230799 copy

Antibiotic versus cranberry in the treatment of uncomplicated urinary infection: a randomized controlled trial

Authorship SCIMAGO INSTITUTIONS RANKINGS

SUMMARY

OBJECTIVE:

This study was designed to determine the effect of cranberry extract used in patients with single urinary tract infections.

METHODS:

Patients with simple-type urinary tract infections were divided into two groups. Treatment with fosfomycin or cranberry tablet was started. On days 1, 3, and 7 of the treatment, whether there was a decrease in the complaints was evaluated with a Likert-type scale. The recovery status of urinary tract infections and the well-being of patients were compared via antibiotic and cranberry groups.

RESULTS:

After the treatment, the leukocyte levels of the cranberry users were at the same level as those of the other group, and the rate of well-being and the portion of patients that reported to be “very well” on days 3 and 7 in the cranberry group was significantly higher compared with the fosfomycin group (p<0.05).

CONCLUSION:

Considering the results of this study, it was determined that the patient's complaints decreased from day 3 and their well-being increased with the use of cranberry only. Specifically, on day 7, the well-being of the cranberry group was higher than that of the fosfomycin group. For this reason, cranberry is a favorable alternative to antibiotics in uncomplicated and simple urinary tract infections.

KEYWORDS:
Cranberry; Fosfomycin; Urinary tract infection

			Fosfomycin		Cranberry		p
			Mean±SD n-%	Median	Mean±SD n-%	Median	p
Age (years)			51.9±13.2	54.0	55.0±14.0	57.0	0.182^m m Mann-Whitney U test;
Gender		F	59–69.4%		58–68.2%		0.868^X² X² chi-square test.
Gender		M	26–30.6%		27–31.8%		0.868^X² X² chi-square test.
Leukocyte
	Before treatment (BT)		19.6±6.8	18.0	16.5±5.1	16.0	0.001 ^m m Mann-Whitney U test;
	Post-treatment (PT)		8.6±14.8	2.0	7.4±13.9	2.0	0.558^m m Mann-Whitney U test;
	BT/PT		-11.0±14.9	-14.0	-9.1±14.5	-12.0	0.080^m m Mann-Whitney U test;
	Intragroup change p.		0.000 ^W w Wilcoxon test;		0.000 ^W w Wilcoxon test;
Well-being
Day 1		So bad	1–1.2%		1–1.2%		0.045 ^X² X² chi-square test.
		Bad	24–28.2%		13–15.3%
		Not bad	53–62.4%		57–67.1%
		Well	7–8.2%		14–16.5%
Day 3		So bad	1–1.2%		0–0.0%		0.038 ^X² X² chi-square test.
		Bad	17–20.0%		9–10.6%
		Not bad	20–23.5%		15–17.6%
		Well	40–47.1%		46–54.1%
		Very well	7–8.2%		15–17.6%
Day 7		So bad	7–8.2%		1–1.2%		0.003 ^X² X² chi-square test.
		Bad	11–12.9%		10–11.8%
		Not bad	4–4.7%		10–11.8%
		Well	45–52.9%		27–31.8%
		Very well	18–21.2%		37–43.5%
Nausea		No	39–45.9%		33–38.8%		0.352^X² X² chi-square test.
Nausea		Yes	46–54.1%		52–61.2%		0.352^X² X² chi-square test.

Associação Médica Brasileira R. São Carlos do Pinhal, 324, 01333-903 São Paulo SP - Brazil, Tel: +55 11 3178-6800, Fax: +55 11 3178-6816 - São Paulo - SP - Brazil
E-mail: ramb@amb.org.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] *Corresponding author: ersinoya@yahoo.com

1 point	So bad
2 point	Bad
3 point	Not bad
4 point	Well
5 point	Very well